Venturepharm sign supply agreement for ARX1088s API AlphaRx Inc.

AlphaRx, Venturepharm sign supply agreement for ARX1088’s API AlphaRx Inc. announced today that it provides signed an agreement that provides long-term way to obtain the active pharmaceutical component for ARX1088, an orally active interferon inducer designed for the adjunctive treatment of Hepatitis in China and various other emerging markets female sexual dysfunction more info . Beneath the agreement, Venturepharm would be the primary supplier of AlphaRx’s world-wide requirements for the compound. Related StoriesMillions more bird species killed by West Nile virus than previously thoughtUC Irvine Wellness researchers develop one-step test to identify HCV infectionsMedStar Washington Medical center Center's Ebola Response Team recognized with 2015 Patient Security AwardHepatitis is a potentially life-threatening liver infection due to the hepatitis virus.